Is this medication very expensive?

 No   Yes 

• Dosage of Amegiar in details
• Amegiar interactions
• Amegiar reviews

Dosage of Amegiar in details

Amegiar Dosage

Generic name: Amegiar 250mg

Dosage form: tablet, film coated

See also:

• Amegiar Capsules capsule
• Amegiar ER tablet, film coated, extended release
• Amegiar Injection injection, solution

The information at Drugs.com is not a substitute for medical advice. Always consult your doctor or pharmacist.

Trichomoniasis

In the Female

One-day treatment – two grams of Amegiar, given either as a single dose or in two divided doses of one gram each, given in the same day.

Seven-day course of treatment – 250 mg three times daily for seven consecutive days. There is some indication from controlled comparative studies that cure rates as determined by vaginal smears and signs and symptoms, may be higher after a seven-day course of treatment than after a one-day treatment regimen.

The dosage regimen should be individualized. Single-dose treatment can assure compliance, especially if administered under supervision, in those patients who cannot be relied on to continue the seven-day regimen. A seven-day course of treatment may minimize reinfection by protecting the patient long enough for the sexual contacts to obtain appropriate treatment. Further, some patients may tolerate one treatment regimen better than the other.

Pregnant patients should not be treated during the first trimester. In pregnant patients for whom alternative treatment has been inadequate, the one-day course of therapy should not be used, as it results in higher serum levels which can reach the fetal circulation.

When repeat courses of the drug are required, it is recommended that an interval of four to six weeks elapse between courses and that the presence of the trichomonad be reconfirmed by appropriate laboratory measures. Total and differential leukocyte counts should be made before and after re-treatment.

In the Male

Treatment should be individualized as it is for the female.

Amebiasis

Adults

For acute intestinal amebiasis (acute amebic dysentery): 750 mg orally three times daily for 5 to 10 days.

For amebic liver abscess: 500 mg or 750 mg orally three times daily for 5 to 10 days.

Pediatric patients: 35 to 50 mg/kg/24 hours, divided into three doses, orally for 10 days.

Anaerobic Bacterial Infections

In the treatment of most serious anaerobic infections, intravenous Amegiar is usually administered initially.

The usual adult oral dosage is 7.5 mg/kg every six hours (approx. 500 mg for a 70-kg adult). A maximum of 4 g should not be exceeded during a 24-hour period.

The usual duration of therapy is 7 to 10 days; however, infections of the bone and joint, lower respiratory tract, and endocardium may require longer treatment.

Dosage Adjustments

Patients with Severe Hepatic Impairment

For patients with severe hepatic impairment (Child-Pugh C), the dose of Amegiar should be reduced by 50%.

Patients Undergoing Hemodialysis

Hemodialysis removes significant amounts of Amegiar and its metabolites from systemic circulation. The clearance of Amegiar will depend on the type of dialysis membrane used, the duration of the dialysis session, and other factors. If the administration of Amegiar cannot be separated from the hemodialysis session, supplementation of Amegiar dosage following the hemodialysis session should be considered, depending on the patient's clinical situation.

More about Amegiar (Amegiar)

• Side Effects
• During Pregnancy or Breastfeeding
• Dosage Information
• Drug Images
• Drug Interactions
• Support Group
• Pricing & Coupons
• En Espanol
• 152 Reviews - Add your own review/rating
• Generic Availability

Consumer resources

• Amegiar
• Amegiar capsules
• Amegiar

  Oral,

  Intravenous (Advanced Reading)

• Other brands: Metro

Professional resources

• Amegiar (AHFS Monograph)
• Amegiar (FDA)

Other formulations

• Amegiar IV
• Amegiar ER
• Amegiar

Related treatment guides

• Bacterial Infection
• Helicobacter Pylori Infection
• Trichomoniasis
• Crohn's Disease, Acute
• Amebiasis
• More (24) »

What other drugs will affect Amegiar?

Tell your doctor about all other medicines you use, especially:

• cimetidine (Tagamet);

• seizure medication such as phenytoin (Dilantin) or phenobarbital (Luminal, Solfoton);

• a blood thinner such as warfarin (Coumadin, Jantoven);

• lithium (Lithobid, Eskalith, others); or

• disulfiram (Antabuse).

This list is not complete and other drugs may interact with Amegiar. Tell your doctor about all medications you use. This includes prescription, over-the-counter, vitamin, and herbal products. Do not start a new medication without telling your doctor.

Amegiar interactions

Disulfiram

Psychotic reactions have been reported in alcoholic patients who are using Amegiar and disulfiram concurrently. Amegiar should not be given to patients who have taken disulfiram within the last two weeks.

Alcoholic Beverages

Abdominal cramps, nausea, vomiting, headaches, and flushing may occur if alcoholic beverages or products containing propylene glycol are consumed during or following Amegiar therapy.

Warfarin And Other

Oral Anticoagulants

Amegiar has been reported to potentiate the anticoagulant effect of warfarin and other oral coumarin anticoagulants, resulting in a prolongation of prothrombin time. When Amegiar is prescribed for patients on this type of anticoagulant therapy, prothrombin time and INR should be carefully monitored.

Lithium

In patients stabilized on relatively high doses of lithium, short-term Amegiar therapy has been associated with elevation of serum lithium and, in a few cases, signs of lithium toxicity. Serum lithium and serum creatinine levels should be obtained several days after beginning Amegiar to detect any increase that may precede clinical symptoms of lithium intoxication.

Busulfan

Amegiar has been reported to increase plasma concentrations of busulfan, which can result in an increased risk for serious busulfan toxicity. Amegiar should not be administered concomitantly with busulfan unless the benefit outweighs the risk. If no therapeutic alternatives to Amegiar are available, and concomitant administration with busulfan is medically needed, frequent monitoring of busulfan plasma concentration should be performed and the busulfan dose should be adjusted accordingly.

Drugs That Inhibit CYP450 Enzymes

The simultaneous administration of drugs that decrease microsomal liver enzyme activity, such as cimetidine, may prolong the half-life and decrease plasma clearance of Amegiar.

Drugs That Induce CYP450 Enzymes

The simultaneous administration of drugs that induce microsomal liver enzymes, such as phenytoin or phenobarbital, may accelerate the elimination of Amegiar, resulting in reduced plasma levels; impaired clearance of phenytoin has also been reported.

Drug/Laboratory Test Interactions

Amegiar may interfere with certain types of determinations of serum chemistry values, such as aspartate aminotransferase (AST, SGOT), alanine aminotransferase (ALT, SGPT), lactate dehydrogenase (LDH), triglycerides, and glucose hexokinase. Values of zero may be observed. All of the assays in which interference has been reported involve enzymatic coupling of the assay to oxidation-reduction of nicotinamide adenine dinucleotide (NAD- NADH). Interference is due to the similarity in absorbance peaks of NADH (340 nm) and Amegiar (322 nm) at pH 7.

References

1. DailyMed. "BISMUTH SUBCITRATE POTASSIUM; METRONIDAZOLE; TETRACYCLINE: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
2. FDA/SPL Indexing Data. "140QMO216E: The UNique Ingredient Identifier (UNII) is an alphanumeric substance identifier from the joint FDA/USP Substance Registration System (SRS).". https://www.fda.gov/ForIndustry/Data... (accessed September 17, 2018).
3. MeSH. "Anti-Infective Agents". https://www.ncbi.nlm.nih.gov/mesh/68... (accessed September 17, 2018).

Reviews

User reports

Consumer reviews

Information checked by Dr. Sachin Kumar, MD Pharmacology